The coexistence of HIV and sickle cell disease (SCD) presents unique clinical challenges, as both conditions significantly impact hematologic and immunologic systems. HIV, by causing immune suppression, exacerbates the complications of SCD, including increased frequency and severity of vaso-occlusive crises, infections, and organ damage. The pathophysiological interplay between these two diseases complicates diagnosis, treatment, and overall management. This review explores the hematologic and immunologic crossroads that occur in HIV-positive SCD patients, discussing how each disease influences the progression and clinical manifestations of the other. The immunosuppressive effects of HIV compound the already heightened inflammatory state present in SCD, leading to a greater risk of infections, organ failure, and accelerated progression of SCD-related complications. The chronic inflammation and endothelial dysfunction caused by SCD, coupled with the immune dysfunction associated with HIV, exacerbate the severity of both conditions. Additionally, certain medications used in the treatment of HIV, such as antiretroviral therapy (ART), can interact with SCD treatments like hydroxyurea, leading to compounded hematologic challenges. This necessitates careful consideration of therapeutic regimens to minimize adverse interactions and optimize patient care.
Emmanuel Ifeanyi Obeagu (Mon,) studied this question.